Prognostic significance of non–muscle-invasive late recurrence after intravesical bacillus Calmette–Guérin therapy in bladder cancer: a multicenter, retrospective real-world study (the Japan Urological Oncology Group)
- 7 August 2026
- journal article
- Published by Oxford University Press (OUP) in Japanese Journal of Clinical Oncology
- Vol. 56 (11) , 1420-1427
Abstract
Background: The prognostic significance of non-muscle-invasive bladder cancer (NMIBC) recurrence after a prolonged disease-free interval following intravesical Bacillus Calmette–Guérin (BCG) therapy remains unclear. This multicenter study evaluated the impact of late recurrence after BCG therapy on oncological outcomes. Methods: This retrospective multicenter study used the Japan Urological Oncology Group database. Among 3226 patients treated with intravesical BCG for NMIBC, 238 with non-muscle-invasive intravesical recurrence ≥1 year after initial BCG therapy were analyzed, after excluding those with muscle-invasive recurrence at first recurrence. Patients were stratified by time to recurrence: 1–2 years and ≥ 2 years. Progression-free survival (PFS) and cancer-specific survival (CSS) were assessed using Kaplan–Meier and Cox proportional hazards analyses. Results: During a median follow-up of 72.7 months, the 5-year PFS and CSS rates were 90.8% and 91.5%, respectively. PFS did not differ significantly between the 1–2-year and ≥ 2-year recurrence groups (log-rank p = 0.300). In contrast, recurrence ≥2 years was associated with significantly worse CSS than recurrence at 1–2 years (log-rank P = .018) and was a significant predictor of worse CSS in univariate analysis (hazard ratio, 8.06; 95% confidence interval, 1.02–62.6; P = .047). Repeat BCG therapy did not significantly improve PFS or CSS in patients with recurrence ≥2 years. Conclusions: NMIBC recurrence occurring ≥2 years after initial BCG therapy may be associated with poorer cancer-specific survival despite similar progression-free survival. Late recurrence should not automatically be considered a favorable prognostic subgroup, and careful surveillance and risk stratification are warranted.Keywords
This publication has 16 references indexed in Scilit:
- Mechanisms, Clinical Trials, and New Treatments for BCG ‐Unresponsive in Nonmuscle Invasive Bladder CancerCancer Medicine, 2025
- Re: Deep Learning Artificial Intelligence Predicts Homologous Recombination Deficiency and Platinum Response from Histologic SlidesEuropean Urology, 2024
- International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin–exposed High-risk Non–muscle-invasive Bladder CancerEuropean Urology, 2022
- European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ)European Urology, 2022
- Does switching the bacillus Calmette-Guérin strain affect clinical outcome in patients with recurrent non–muscle-invasive bladder cancer after initial bacillus Calmette-Guérin therapy?Urologic Oncology: Seminars and Original Investigations, 2018
- Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE TrialEuropean Urology, 2014
- Epidemiology and Risk Factors of Urothelial Bladder CancerEuropean Urology, 2013
- Cancer immunoediting: from immunosurveillance to tumor escapeNature Immunology, 2002
- Long-term results of intravesical bacillus calmette-guérin therapy for stage T1 superficial bladder cancerUrology, 2000
- MAINTENANCE BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY FOR RECURRENT TA, T1 AND CARCINOMA IN SITU TRANSITIONAL CELL CARCINOMA OF THE BLADDER: A RANDOMIZED SOUTHWEST ONCOLOGY GROUP STUDYJournal of Urology, 2000